Liquidia (LQDA) Q4 2025 earnings summary

Executive summary

• Achieved rapid commercial success with YUTREPIA, reaching profitability within 120 days of launch and recording one of the top specialty drug launches in the past five years, with robust momentum into 2026.

• Over 3,600 unique patient referrals and more than 2,900 patients treated since launch, with a prescriber base expanded to 860 and 25% of physicians referring five or more patients.

• Achieved second consecutive quarter of profitability in Q4 2025, with net income of $14.6 million and adjusted EBITDA of $27.3 million.

• Initiated multiple new clinical studies to expand indications and combinations, including pivotal trials for L606 and studies for systemic sclerosis-associated Raynaud's phenomenon and PH-COPD.

• Confident in building a billion-dollar franchise by 2027, with continued growth and deepening adoption expected.

Financial highlights

• YUTREPIA generated $148.3 million in net product sales for 2025, including $90.1 million in Q4, representing 74% sequential growth from Q3.

• Total revenue for 2025 was $158.3 million, up from $14.0 million in 2024.

• Operating income improved to $19.8 million in Q4 2025, compared to a loss of $121.3 million in 2024.

• Ended 2025 with $190.7 million in cash and cash equivalents, generating $33.2 million positive cash flow in Q4.

• Selling, general, and administrative expenses rose to $157.2 million in 2025, mainly due to commercialization efforts.

Outlook and guidance

• Projecting continued strong growth in 2026, with no anticipated impediments to current trajectory and plans to deepen prescriber adoption and expand sales force.

• Targeting at least $1 billion in revenue by 2027, supported by market expansion and increased sales force.

• Confident in maintaining high patient add rates and robust funnel visibility despite emerging competition.